Alector Stock Price, News & Analysis

Alector, Inc. (Nasdaq: ALEC) reported promising results from the INFRONT-2 Phase 2 clinical trial of AL001 (latozinemab), showing a 54% annual delay in disease progression for FTD-C9orf72 patients compared to controls. The drug increased progranulin levels significantly, supporting its role in treating neurodegenerative diseases. Alector's cash reserves stand at $868.6 million, ensuring operational funds through mid-2024. Leadership has been strengthened with new appointments, enhancing their clinical and financial strategies.

Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced its participation in the BofA Securities 2022 Healthcare Conference. The event will occur on May 12, 2022, at 11:20 a.m. PT, and will feature a fireside chat with management. A live webcast can be accessed through the Alector website, with a replay available for 90 days post-event. Alector specializes in therapeutic approaches for neurodegenerative diseases, targeting immune dysfunction in conditions such as Alzheimer's and frontotemporal dementia.

Alector, a biotechnology company focused on immuno-neurology, has appointed Dr. Gary Romano as the new Chief Medical Officer, effective May 23, 2022. Dr. Romano, an expert in neurodegeneration with over 25 years of experience, will oversee clinical development and operations. His previous roles include leadership at Passage Bio and Janssen. The company expressed gratitude to interim CMO Dr. Sam Jackson for his contributions. Dr. Romano aims to advance Alector's pipeline targeting neurodegenerative diseases, enhancing its strategy in clinical research and drug development.

Alector presented promising results from the INFRONT-2 Phase 2 clinical trial of AL001 (latozinemab) in patients with frontotemporal dementia (FTD) carrying the C9orf72 mutation. The trial showed that treatment led to increased levels of progranulin and a trend towards a delay in disease progression by approximately 54% compared to matched controls. After 12 months of treatment, latozinemab was well tolerated, with stability in neurofilament light chain levels and a reduction in GFAP levels, suggesting potential benefits in neurodegenerative disease management.

Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced presentations at two upcoming investor conferences. The first is at the Barclays Global Healthcare Conference in Miami, scheduled for March 16, 2022, at 3:20 p.m. ET. The second is the Stifel CNS Days Virtual event on March 28, 2022, at 11:30 a.m. ET. Both presentations will be available via live webcasts, with replays accessible for 90 days on Alector's website. Alector aims to treat neurodegenerative diseases by addressing immune dysfunction.

Alector (Nasdaq: ALEC) announced an oral presentation at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases, scheduled for March 15-20, 2022, in Barcelona, Spain. The presentation will showcase the 12-month results from the INFRONT-2 Phase 2 study of AL001 in Frontotemporal Dementia patients with a C9orf72 mutation. Alector will also host a conference call on March 15, 2022, at 8:30 a.m. ET to discuss these findings.

For more details, visit www.alector.com.

Alector, Inc. (Nasdaq: ALEC) announced on March 1, 2022, that its board's compensation committee granted newly appointed CFO, Marc Grasso, M.D., an inducement equity grant consisting of stock options for 450,000 shares. The options' exercise price is set at $15.49, matching the stock's closing price on the grant date. These options vest monthly over four years, contingent on Dr. Grasso's continued employment. Alector focuses on immuno-neurology, targeting immune dysfunction to develop therapies for neurodegenerative diseases.

Alector, a clinical-stage biotechnology company, will participate in a panel discussion at the Cowen Annual Health Care Conference on March 8, 2022, at 2:10 p.m. ET. The event will be available via a live webcast on Alector's 'Events & Presentations' page in the Investors section of their website. After the event, a replay will be accessible for 30 days. Alector focuses on immuno-neurology therapies targeting neurodegenerative diseases by repairing immune dysfunction and aims to develop treatments for conditions like frontotemporal dementia and Alzheimer’s disease.

Alector, Inc. (Nasdaq: ALEC) reported its fourth quarter and full year 2021 financial results. As of December 31, 2021, the company had cash reserves totaling $735.3 million, which increased to over $900 million after receiving a $200 million payment from GlaxoSmithKline (GSK) in January 2022. Collaboration revenue surged to $14 million for the quarter and $207 million for the year, significantly up from previous periods. However, Alector reported a net loss of $55.6 million in Q4 2021, slightly higher than the previous year's loss. The company anticipates sufficient funds to support operations through mid-2024.